Actively Recruiting
Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel
Led by First Affiliated Hospital of Guangxi Medical University · Updated on 2025-08-17
318
Participants Needed
2
Research Sites
75 weeks
Total Duration
On this page
Sponsors
F
First Affiliated Hospital of Guangxi Medical University
Lead Sponsor
P
People's Hospital of Guangxi Zhuang Autonomous Region
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate and compare the efficacy and safety of three commonly used antiparasitic drugs-albendazole, tribendimidine, and praziquantel-for the treatment of clonorchiasis, a liver fluke infection acquired by consuming raw or undercooked freshwater fish. This study aims to answer the following primary questions: How effective is each drug in achieving parasitological cure, as measured by clearance of Clonorchis sinensis eggs in stool? What types and frequencies of adverse events are associated with each treatment? Participants in this randomized, open-label trial will: Be randomly assigned to receive one of the three study drugs according to a predefined dosing regimen. Provide stool samples before treatment and at follow-up to assess for Clonorchis sinensis eggs. Undergo a second round of the same treatment regimen and repeated stool examination if eggs are still detected after the first course. Attend follow-up visits, which include symptom assessment, blood tests (hematology and liver function), and abdominal ultrasonography focusing on hepatobiliary changes. Report any side effects, discomfort, or adverse reactions experienced during or after treatment. The findings from this study will help inform optimal therapeutic strategies for clonorchiasis in outpatient clinical settings.
CONDITIONS
Official Title
Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Confirmed Clonorchis sinensis infection by detecting eggs or adult worms in stool or bile drainage fluid
- Willing and able to provide written informed consent and follow study procedures
You will not qualify if you...
- Known allergy to albendazole, praziquantel, or tribendimidine
- Supraventricular tachycardia or atrial fibrillation confirmed by ECG
- Diagnosed neurocysticercosis or ocular cysticercosis
- Presence of gallbladder stones or bile duct obstruction confirmed by ultrasound
- Severe liver, kidney, or heart dysfunction or active peptic ulcer disease
- Pregnant or breastfeeding individuals or those unwilling to use effective contraception during and 3 months after the study
- Expected inability to complete the study due to relocation, withdrawal, or other adherence issues
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China, 530021
Not Yet Recruiting
2
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China, 530021
Actively Recruiting
Research Team
H
Hongliang Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here